MedPath

Escitalopram

Generic Name
Escitalopram
Brand Names
Cipralex, Lexapro
Drug Type
Small Molecule
Chemical Formula
C20H21FN2O
CAS Number
128196-01-0
Unique Ingredient Identifier
4O4S742ANY
Background

Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic citalopram. It is used to restore serotonergic function in the treatment of depression and anxiety. Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with some evidence suggesting that the R-enantiomer of racemic citalopram actively dampens the activity of escitalopram rather than existing simply as an inactive enantiomer. Amongst SSRIs, escitalopram exerts the highest degree of selectivity for the serotonin transporter (SERT) relative to other off-targets which may explain its lower rates of adverse effects as compared to other agents in this class. Escitalopram also differentiates itself from other SSRIs via allosteric action on its target - this may be the mechanism responsible for its observed superior efficacy and faster onset compared to other SSRIs.

Indication

Escitalopram is indicated for the acute and maintenance treatment of major depressive disorder (MDD) in adults and pediatric patients 12 years old and older and for the acute treatment of generalized anxiety disorder (GAD) in adults and pediatric patients 7 years old and older. It is additionally indicated for symptomatic relief of obsessive-compulsive disorder (OCD) in Canada.

Associated Conditions
Anxiety, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD)
Associated Therapies
-

Cognitive Dysfunction in MDD Patients

Phase 4
Conditions
Major Depressive Disorder
Interventions
First Posted Date
2017-06-14
Last Posted Date
2019-01-10
Lead Sponsor
Oleg Levada
Target Recruit Count
150
Registration Number
NCT03187093
Locations
🇺🇦

State Institution "Zaporizhzhia Medical Academy of Postgraduate Education Ministry of Health of Ukraine", Zaporizhzhia, Ukraine

Serotonin and Motor Plasticity

Phase 4
Conditions
Healthy Controls
Interventions
Drug: Escitalopram
Drug: Placebo
First Posted Date
2017-05-22
Last Posted Date
2017-05-22
Lead Sponsor
Max Planck Institute for Human Cognitive and Brain Sciences
Target Recruit Count
60
Registration Number
NCT03162185
Locations
🇩🇪

Max Planck Institute for Cognition and Brain Sciences, Leipzig, Saxony, Germany

A Diagnosis and Treatment Optimization Study of Depression Based on the Neurological Mechanism of Reward System

Not Applicable
Conditions
Diagnosis and Treatment of Depression
Interventions
First Posted Date
2017-05-11
Last Posted Date
2019-12-13
Lead Sponsor
Peking University
Target Recruit Count
120
Registration Number
NCT03148522
Locations
🇨🇳

Yun-Ai SU, Beijing, Beijing, China

Effectiveness Study of Scopolamine Combined With Escitalopram in Patients With MDD

Phase 4
Completed
Conditions
Major Depressive Disorder
Interventions
First Posted Date
2017-04-27
Last Posted Date
2018-12-26
Lead Sponsor
Capital Medical University
Target Recruit Count
66
Registration Number
NCT03131050
Locations
🇨🇳

Beijing Anding Hospital, Beijing, China

Escitalopram in the Treatment of Adolescents With Major Depressive Disorder or Anxiety Disorders

Phase 4
Conditions
Anxiety Disorders
Major Depressive Disorder
Interventions
First Posted Date
2017-04-20
Last Posted Date
2017-04-20
Lead Sponsor
Erzurum Regional Training & Research Hospital
Target Recruit Count
60
Registration Number
NCT03122158
Locations
🇹🇷

ErzurumRTRH, Erzurum, Palandöken, Turkey

Escitalopram for Agitation in Alzheimer's Disease

Phase 3
Active, not recruiting
Conditions
Dementia
Interventions
Drug: Placebo
Drug: Escitalopram
First Posted Date
2017-04-11
Last Posted Date
2024-02-29
Lead Sponsor
JHSPH Center for Clinical Trials
Target Recruit Count
187
Registration Number
NCT03108846
Locations
🇺🇸

Hackensack Meridian Health, Hackensack, New Jersey, United States

🇺🇸

Baylor AT&T Memory Center, Dallas, Texas, United States

🇺🇸

University of California Los Angeles/VA Greater Los Angeles Healthcare System, Los Angeles, California, United States

and more 26 locations

Establishment of Cessation Therapy by Clinical Trials for Subjects With Betel-quid Dependence and Oral Pre-cancer

Phase 2
Terminated
Conditions
Addiction
Interventions
First Posted Date
2017-01-05
Last Posted Date
2019-07-24
Lead Sponsor
China Medical University Hospital
Target Recruit Count
90
Registration Number
NCT03010761

Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

Terminated
Conditions
Bipolar Disorder
First Posted Date
2016-09-08
Last Posted Date
2024-03-12
Lead Sponsor
University of New Mexico
Target Recruit Count
1037352
Registration Number
NCT02893371
Locations
🇺🇸

Christophe G Lambert, Albuquerque, New Mexico, United States

Treatment Outcome in Major Depressive Disorder

Phase 1
Completed
Conditions
Major Depressive Disorder
Interventions
First Posted Date
2016-08-16
Last Posted Date
2019-10-16
Lead Sponsor
Rigshospitalet, Denmark
Target Recruit Count
100
Registration Number
NCT02869035
Locations
🇩🇰

Neurobiology Research Unit, Rigshospitalet, Copenhagen, Denmark

Neurofunctional Predictors of Escitalopram Treatment Response in Adolescents With Anxiety

Not Applicable
Completed
Conditions
Anxiety
Interventions
Other: Placebo
Drug: Escitalopram
First Posted Date
2016-06-30
Last Posted Date
2020-11-06
Lead Sponsor
University of Cincinnati
Target Recruit Count
84
Registration Number
NCT02818751
Locations
🇺🇸

University of Cincinnati, Department of Psychiatry & Behavioral Neuroscience, Cincinnati, Ohio, United States

© Copyright 2025. All Rights Reserved by MedPath